search
Back to results

Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock. (HSHC00582434)

Primary Purpose

Septic Shock

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Hydrocortisone hemisuccinate
Sponsored by
Association Niçoise de Réanimation Médicale
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • patients over 18 years old
  • septic shock in accordance with the American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee criteria. Septic shock was managed in accordance with the 2004 edition of the Surviving Sepsis Campaign guidelines.
  • no minimal vasopressor dose was needed to enter the trial.

Exclusion Criteria:

  • medical history of adrenal insufficiency
  • ongoing corticosteroid treatment
  • pregnancy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    200 mg group

    300 mg group

    Arm Description

    Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.

    Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.

    Outcomes

    Primary Outcome Measures

    Mortality
    The primary end point was to determine a difference in 28-day mortality between the 200-mg and 300-mg groups.

    Secondary Outcome Measures

    Incidence of permanent shock between groups
    Permanent shock (PS) was defined as permanent catecholamine support (epinephrine or norepinephrine) in the ICU, from the onset of septic shock to death without a period of reversal.
    Incidence of shock relapse between groups
    Shock relapse (SR) was defined as recurrence of septic shock requiring catecholamine resumption.
    Incidence of post hydrocortisone hemodynamic rebound between groups
    Post hydrocortisone hemodynamic rebound (PHHR) was defined as SR within 48 hours after hydrocortisone cessation.
    Incidence of adverse events between groups.
    Incidences of hemorrhagic events, superinfections and the amount of needed insulin were compared between the two groups.

    Full Information

    First Posted
    May 10, 2016
    Last Updated
    May 20, 2016
    Sponsor
    Association Niçoise de Réanimation Médicale
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02768740
    Brief Title
    Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.
    Acronym
    HSHC00582434
    Official Title
    Double Blinded, Randomized Trial, Comparing Intravenous Bolus of 50 mg of Hydrocortisone Every 6 Hours for 7 Days With a Continuous Infusion of 300 mg Per Day of Hydrocortisone 300-mg Group During 5 Days in the Treatment of Septic Shock.
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    May 2016
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2008 (undefined)
    Primary Completion Date
    May 2010 (Actual)
    Study Completion Date
    September 2014 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Association Niçoise de Réanimation Médicale

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    We performed a multicenter, prospective, randomized, double-blind, pilot study in four adult medical intensive care units. Patients presenting septic shock were rapidly administered one of two regimens of hydrocortisone, either a 50-mg intravenous bolus every six hours during seven days (200-mg group) or a 100-mg initial bolus followed by a continuous infusion of 300 mg daily for five days (300-mg group). Hydrocortisone was stopped abruptly at the end of treatment.
    Detailed Description
    Hydrocortisone hemisuccinate (Hydrocortisone Upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent. The placebo was saline serum supplied as 10 ml ampoules. The study drugs were administered according to two protocols. In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days. In the two groups, hydrocortisone was stopped abruptly at the end of treatment. The investigators had the choice or resuming hydrocortisone at the end of the fifth day if deemed necessary.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Septic Shock

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    120 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    200 mg group
    Arm Type
    Active Comparator
    Arm Description
    Patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days.
    Arm Title
    300 mg group
    Arm Type
    Experimental
    Arm Description
    Patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
    Intervention Type
    Drug
    Intervention Name(s)
    Hydrocortisone hemisuccinate
    Other Intervention Name(s)
    Saline solution as placebo
    Intervention Description
    In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
    Primary Outcome Measure Information:
    Title
    Mortality
    Description
    The primary end point was to determine a difference in 28-day mortality between the 200-mg and 300-mg groups.
    Time Frame
    28-day
    Secondary Outcome Measure Information:
    Title
    Incidence of permanent shock between groups
    Description
    Permanent shock (PS) was defined as permanent catecholamine support (epinephrine or norepinephrine) in the ICU, from the onset of septic shock to death without a period of reversal.
    Time Frame
    28-day
    Title
    Incidence of shock relapse between groups
    Description
    Shock relapse (SR) was defined as recurrence of septic shock requiring catecholamine resumption.
    Time Frame
    28-day
    Title
    Incidence of post hydrocortisone hemodynamic rebound between groups
    Description
    Post hydrocortisone hemodynamic rebound (PHHR) was defined as SR within 48 hours after hydrocortisone cessation.
    Time Frame
    28-day
    Title
    Incidence of adverse events between groups.
    Description
    Incidences of hemorrhagic events, superinfections and the amount of needed insulin were compared between the two groups.
    Time Frame
    28-day

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: patients over 18 years old septic shock in accordance with the American College of Chest Physicians/Society of Critical Care Medicine Consensus Committee criteria. Septic shock was managed in accordance with the 2004 edition of the Surviving Sepsis Campaign guidelines. no minimal vasopressor dose was needed to enter the trial. Exclusion Criteria: medical history of adrenal insufficiency ongoing corticosteroid treatment pregnancy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Gilles Bernardin, M.D.
    Organizational Affiliation
    Association Niçoise de Réanimation Médicale
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    IPD Sharing Plan Description
    The data are available for additional analysis

    Learn more about this trial

    Hydrocortisone 50 mg Every 6 Hours Compared to Hydrocortisone 300 mg Per Day in Treatment of Septic Shock.

    We'll reach out to this number within 24 hrs